A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX After Administration of Repeated Doses for 3 Days in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2016
At a glance
- Drugs AR C165395XX (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 17 May 2016 Time frame for primary endpoints has changed.
- 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.